Hydroxytryptamine uptake inhibitors block para- methoxyamphetamine-induced 5-HT release

Area of Science:

• Neuropharmacology
• Central Nervous System (CNS) Research

Background:

• Myolonic twitch activity (MTA) in suprahyoideal muscles is linked to brain serotonin (5-HT) release.
• p-methoxyamphetamine (PMA) is known to activate MTA, likely through 5-HT pathways.

Purpose of the Study:

• To investigate the role of central 5-HT release in PMA-induced MTA.
• To determine the efficacy of specific 5-HT uptake inhibitors in blocking PMA-induced MTA and 5-HT release.

Main Methods:

• Rats anesthetized with urethane were administered PMA to induce MTA.
• The effects of chlorimipramine, fluoxetine, and desipramine on PMA-induced MTA were assessed.
• [3H]-5-HT release in cerebrospinal fluid was measured after PMA administration and treatment with uptake inhibitors.

Main Results:

• Chlorimipramine and fluoxetine dose-dependently blocked PMA-induced MTA and [3H]-5-HT release.
• Desipramine showed minimal inhibition of PMA-induced [3H]-5-HT release.
• Methysergide blocked 5-hydroxytryptophan-induced MTA, while chlorimipramine did not.

Conclusions:

• PMA-induced MTA is mediated by the release of 5-HT in the central nervous system.
• Selective serotonin reuptake inhibitors (SSRIs) effectively block PMA-induced 5-HT release and subsequent MTA.
• These findings support the hypothesis that SSRIs act centrally to inhibit PMA-induced effects.